Isotetrandrine protects against lipopolysaccharide-induced acute lung injury by suppression of mitogen-activated protein kinase and nuclear factor-kappa B

The Journal of Surgical Research
Xian-ming LiangZhen-ling Zeng

Abstract

Mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-κB) signaling pathways are pleiotropic regulator of many genes involved in lipopolysaccharide (LPS)-induced acute lung injury (ALI). The present study aimed to reveal the protective effect of isotetrandrine (ITD), a small molecule inhibitor, on various aspects of LPS-induced inflammation in vitro and in vivo. In vitro, RAW 264.7 cells were pretreated with different dose of ITD 1 h before treatment with 1 mg/L of LPS. In vivo, to induce ALI, male BALB/c mice were injected intranasally with LPS and treated with ITD (20 and 40 mg/kg) 1 h before LPS. In vitro, the cytokine levels of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 in supernatant were reduced by ITD. Meanwhile, in vivo, pulmonary inflammatory cell infiltration, myeloperoxidase activity, total cells, neutrophils, macrophages, along with the levels of tumor necrosis factor-α, IL-1β, and IL-6 in bronchoalveolar lavage fluid were dose-dependently attenuated by ITD. Furthermore, our data showed that ITD significantly inhibited the activation of MAPK and NF-κB, which are induced by LPS in ALI model. These results suggested that ITD dose-dependently suppressed the severity of LPS-induced ALI by ...Continue Reading

References

Apr 10, 1999·The Journal of Biological Chemistry·J C ChowF Gusovsky
Mar 4, 2000·The European Respiratory Journal·D S FaffeW A Zin
Apr 24, 2001·American Journal of Respiratory and Critical Care Medicine·J D RicardG Saumon
Jul 30, 2002·British Journal of Pharmacology·Angeliki XagorariAndreas Papapetropoulos
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Jeffrey G Wright, John W Christman
Jan 27, 2004·The Journal of Pathology·Madhav Bhatia, Shabbir Moochhala
Dec 5, 2006·The Journal of Clinical Investigation·Alexander ZarbockKlaus Ley
May 15, 2007·American Journal of Physiology. Lung Cellular and Molecular Physiology·Wen-Feng FangIvor S Douglas
May 12, 2009·Biochemical Pharmacology·Katrin Schuh, Andreas Pahl
Jul 12, 2011·Critical Care Clinics·Krishnan Raghavendran, Lena M Napolitano
Mar 24, 2012·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Zhijian YouShanglong Yao

❮ Previous
Next ❯

Citations

Feb 24, 2015·International Immunopharmacology·Hsian-He HsuShi-Jye Chu
May 15, 2016·International Immunopharmacology·Xia LiJi-Xing Nan
Aug 16, 2017·International Journal of Molecular Sciences·Wen-I LiaoShi-Jye Chu
Oct 30, 2020·Zeitschrift Für Naturforschung. C, a Journal of Biosciences·Wencheng XuToshihiko Hirano
Mar 5, 2021·Frontiers in Pharmacology·Mohammad Bagher MajnooniJavier Echeverría

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.